Works by Seijas-Amigo, José


Results: 4
    1

    Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID‐REAL registry.

    Published in:
    European Journal of Clinical Investigation, 2022, v. 52, n. 12, p. 1, doi. 10.1111/eci.13863
    By:
    • Cordero, Alberto;
    • Fernández Olmo, Mª. Rosa;
    • Cortez Quiroga, Gustavo A.;
    • Romero‐Menor, Cesar;
    • Fácila, Lorenzo;
    • Seijas‐Amigo, José;
    • Rondán Murillo, Juan;
    • Sandin, Miriam;
    • Rodríguez‐Mañero, Moisés;
    • Bello Mora, María C.;
    • Valle, Alfonso;
    • Fornovi, Aisa;
    • Freixa Pamias, Roman;
    • Bañeras, Jordi;
    • Blanch García, Pedro;
    • Clemente Lorenzo, María Milagros;
    • Sánchez‐Álvarez, Sergio;
    • López‐Rodríguez, Luis;
    • González‐Juanatey, José R.
    Publication type:
    Article
    2
    3
    4

    Cost–Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.

    Published in:
    Diseases, 2024, v. 12, n. 10, p. 244, doi. 10.3390/diseases12100244
    By:
    • Seijas-Amigo, José;
    • Mauriz-Montero, Maria José;
    • Suarez-Artime, Pedro;
    • Gayoso-Rey, Mónica;
    • Reyes-Santías, Francisco;
    • Estany-Gestal, Ana;
    • Casas-Martínez, Antonia;
    • González-Freire, Lara;
    • Rodriguez-Vazquez, Ana;
    • Pérez-Rodriguez, Natalia;
    • Villaverde-Piñeiro, Laura;
    • Castro-Rubinos, Concepción;
    • Espino-Paisán, Esther;
    • Cordova-Arevalo, Octavio;
    • Rodriguez-Penas, Diego;
    • Cardeso-Paredes, Begoña;
    • Ribeiro-Ferreiro, Marta;
    • Rodríguez-Mañero, Moisés;
    • Cordero, Alberto;
    • González-Juanatey, José R.
    Publication type:
    Article